Clinical Trial

Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
* To find the recommended dose of axatilimab given alone and in combination with ruxolitinib in patients with MF and CMML. * To learn if axatilimab given in combination with ruxolitinib can help to control MF and CMML.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-08-13; most recent amendment 2026-07-14.
Status change: Not Yet Recruiting → Recruiting 2026-01-02
Trial Details
NCT Number NCT07128381
Lead Sponsor M.D. Anderson Cancer Center
Collaborators: Incyte, Inc
Conditions Myelofibrosis (MF), Chronic Myelomonocytic Leukemia (CMML)
Enrollment 66 participants
Start Date 2026-01-02
Primary Completion 2031-07-31 (estimated)
Study Completion 2033-07-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-15